Literature DB >> 3816928

Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

H Albin, J M Ragnaud, F Demotes-Mainard, G Vinçon, M Couzineau, C Wone.   

Abstract

The kinetics of ceftriaxone was investigated in 8 patients without infection, who were receiving continuous ambulatory peritoneal dialysis (CAPD). Ceftriaxone 1 g was injected i.v. and 1 g was given intraperitoneally in the CAPD fluid during a 4-h dwell time. Ceftriaxone was assayed by HPLC. After intravenous administration, the kinetic parameters of ceftriaxone were: plasma t1/2, 12.3 h, total plasma clearance, 14.0 ml/min, volume of distribution at steady state 0.18 l/kg, and peritoneal clearance 0.59 ml/min. Over 72 hours only 5.5% of the dose was eliminated by the peritoneal route. After intraperitoneal administration, ceftriaxone rapidly appeared in serum; the absorption t1/2 was 1.1 h and the mean peak concentration was 38.8 micrograms/ml. The absorption of ceftriaxone from the peritoneal space was 39%. A single 1.0 g IP dose led to serum and dialysate concentrations of ceftriaxone above the minimum inhibitory concentration for susceptible pathogens for 24 hours.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3816928     DOI: 10.1007/bf00613528

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic.

Authors:  M E Pickup; H A Bird; J R Lowe; L Lees; V Wright
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

2.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults.

Authors:  A A Pollock; P E Tee; I H Patel; J Spicehandler; M S Simberkoff; J J Rahal
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Pharmacokinetics of cefoperazone in patients undergoing chronic ambulatory peritoneal dialysis: clinical and pathophysiological implications.

Authors:  J E Hodler; R L Galeazzi; B Frey; M Rudhardt; A J Seiler
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.

Authors:  D Cohen; G B Appel; B Scully; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

5.  Pharmacokinetics of intraperitoneal cefotaxime treatment of peritonitis in patients on continuous ambulatory peritoneal dialysis.

Authors:  J Petersen; R D Stewart; G R Catto; N Edward
Journal:  Nephron       Date:  1985       Impact factor: 2.847

6.  Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment.

Authors:  I H Patel; J G Sugihara; R E Weinfeld; E G Wong; A W Siemsen; S J Berman
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis.

Authors:  T Y Ti; L Fortin; J H Kreeft; D S East; R I Ogilvie; P J Somerville
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

8.  Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vincon; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis.

Authors:  A Arvidsson; G Alván; A Tranaeus; A S Malmborg
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.

Authors:  H C Albin; F M Demotes-Mainard; J L Bouchet; G A Vincon; C Martin-Dupont
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  6 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 2.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

4.  Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin.

Authors:  Anne B Taegtmeyer; Nina Kononowa; Dominique Fasel; Manuel Haschke; Felix Burkhalter
Journal:  Perit Dial Int       Date:  2016 Jan-Feb       Impact factor: 1.756

5.  Ceftriaxone-induced acute encephalopathy in a peritoneal dialysis patient.

Authors:  Sami Safadi; Michael Mao; John J Dillon
Journal:  Case Rep Nephrol       Date:  2014-12-07

Review 6.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.